Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Incyte Corporation, TG Therapeutics, Inc., and Verastem, Inc.

Community Practice Connections™: The Evolving Role of PI3K Inhibitors for the Management of Hematologic Malignancies: Integration of Recent Data Sets Into Clinical Practice

Release Date: January 31, 2021
Expiration Date: January 31, 2022

Activity Overview

Dysregulation of phosphatidylinositol 3-kinase (PI3K) activity is a common feature in human cancer cells. The activated PI3K pathway, including downstream signaling via Akt and mTOR, imparts competitive growth and survival, increased metastatic stability, and resistance to conventional therapy for malignant tumors. Targets of PI3K, an isoform of PI3K that is essential for B-cell survival, are of considerable interest in B-cell malignancies. Over the past several years, three PI3K inhibitors have been approved for the treatment of patients with hematologic malignancies, and now many novel PI3K inhibitors at various stages of development are under investigation as well. Clinicians will need to evaluate the latest clinical data on the efficacy and safety of this class of agents to understand which of their patients will most likely benefit from this treatment strategy.

The Community Practice Connection™ provides an in-depth review of some of the key highlights from the 62nd American Society of Hematology Annual Meeting & Exposition (ASH 2020) held in December 2020. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with hematologic malignancies, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Incyte Corporation, TG Therapeutics, Inc., and Verastem, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward hematologists, medical oncologists, and other oncology healthcare professionals interested in the latest advances in the treatment of patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with hematologic malignancies are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Examine the rationale supporting the use of PI3K inhibitors in the treatment of patients with hematologic malignancies in the relapsed and refractory settings
  • Recognize the role of PI3K inhibitors in the treatment of hematologic malignancies in the relapsed and refractory settings
  • Review emerging data as well as planned and ongoing trials focused on evaluating current and emerging PI3K inhibitors in the treatment of hematologic malignancies
  • Create individualized plans to educate patients and manage treatment-related toxicities in patients being treated with PI3K inhibitors

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Javier Pinilla-Ibarz, MD, PhD
Javier Pinilla-Ibarz, MD, PhD
Senior Member
Head of Lymphoma Section and Director of Immunotherapy
Malignant Hematology Department
H. Lee Moffitt Cancer Center
Professor, Department of Oncologic Sciences
University of South Florida
Tampa, FL

Disclosures: Grant Research Support: TG Therapeutics; Consultant: AbbVie, AstraZeneca, Janssen, TG Therapeutics; Consultant: AbbVie, AstraZeneca, Janssen, TG Therapeutics; Speakers Bureau: AbbVie, AstraZeneca, Janssen

Catherine C. Coombs, MD
Catherine C. Coombs, MD
Assistant Professor of Medicine
Division of Hematology and Oncology
The University of North Carolina Cancer Center
Chapel Hill, NC

Disclosures: Consultant: AbbVie

Alexey Danilov, MD, PhD
Alexey Danilov, MD, PhD
Associate Director, Toni Stephenson Lymphoma Center
Professor, Department of Hematology & Hematopoietic Cell Transplantation
City of Hope Comprehensive Cancer Center
Duarte, CA

Disclosures: Grant Research Support: Aptose Biosciences, AstraZeneca, Bayer Oncology, Bristol Myers Squibb, Genentech, Gilead Sciences, Takeda Oncology, Verastem Oncology; Consultant: AbbVie, AstraZeneca, Bayer Oncology, BeiGene, Bristol Myers Squibb, Genentech, GenMab, Karyopharm, Nurix Therapeutics, Pharmacyclics, Rigel Pharmaceuticals, TG Therapeutics

Sameh Gaballa, MD
Sameh Gaballa, MD
Assistant Member
Malignant Hematology Division
H. Lee Moffitt Cancer Center
Tampa, FL

Disclosures: Consultant: BeiGene, Celgene Corporation, Epizyme, Janssen Pharmaceutica, Pharmacyclics; Speakers Bureau: Janssen Pharmaceutica, Pharmacyclics

Joanna Rhodes, MD, MSCE
Joanna Rhodes, MD, MSCE
Assistant Professor
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Northwell Health Cancer Institute
New Hyde Park, NY

Disclosures: Grant Research Support: Conquer Cancer Foundation Young Investigator Award; Consultant: AbbVie, AstraZeneca, Genentech, Verastem, Pharmacyclics

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By